ASSESSMENT OF THE EFFECT OF LONG-TERM GLUCOCORTICOID USE ON THE RISK OF TYPE 2 DIABETES MELLITUS IN PATIENTS WITH GOUT

Abstract

Abstract: The gout is the most common form of inflammatory arthritis, and in the United States alone it affects about 3.9% (9.2 million) of the country's population [1]. Despite the fact that the aetiology and pathogenesis of gout are well studied and there are effective drugs that allow you to fully control the disease, adherence to treatment remains unsatisfactory, and most patients do not receive adequate urate-reducing therapy [2-4]. One of the reasons for low adherence to therapy is the fear of the risk of exacerbation of gout arthritis, the likelihood of which increases when taking any urath-reducing drugs in the first months of therapy [5–7]. The appointment of preventive treatment can prevent repeated gout attacks. Such tactics of using anti-inflammatory drugs for an average of 6 months in parallel with the intake of urate-reducing therapy (UST) is proposed for practical use in patients with gout by most national and international recommendations [8][9]. The most widely used drugs for the prevention of attacks are colchicin, non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids (GC) [10]. The latter are the least studied: studies on the long-term use of low doses of HA in patients with gout have not yet been conducted. While the use of a short course of GC to relieve acute attacks of gouty arthritis is considered safe and not inferior, and, according to some data exceeding NSAIDs in this regard [11-13], the data on long-term use of HA in gout are very limited and do not contain information on the safety of such therapy, including its impact on the risk of developing carbohydrate metabolism disorders in these patients [5][14].